~~11. A modified release dosage form comprising:~~

~~2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof, wherein said dosage form, after a single administration to a human subject in need of treatment thereof produces in the subject a mean maximum plasma concentration (C_{max}) of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof between about 0.8 µg/mL to about 1.7 µg/mL.~~

~~12. The dosage form of claim 11, wherein the dosage form provides 80 mg of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof.~~

~~13. The dosage form of claim 11, wherein the dosage form exhibits a mean C_{max} of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid of between about 0.8 µg/mL to about 1.6 µg/mL.~~

~~14. The dosage form of claim 11, wherein the dosage form exhibits a mean C_{max} of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid of between about 0.8 µg/mL to about 1.5 µg/mL.~~

~~15. The dosage form of claim 11, wherein the dosage form exhibits a mean C_{max} of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid of between 1.13 µg/mL to about 1.29 µg/mL.~~

~~16. The dosage form of claim 11, wherein the dosage form exhibits a mean C_{max} of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid of about 1.19 µg/mL.~~

~~17. The dosage form of claim 11, wherein the dosage form, after a single administration to a human subject in need of treatment thereof produces in the subject a mean time to peak concentration (T_{max}) of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid of between about 1.5 hours to about 3.0 hours.~~

~~18. The dosage form of claim 11, wherein the dosage form, after a single administration to a human subject in need of treatment, thereof produces in the subject a mean time to peak concentration (T_{max}) of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid of between about 3.0 hours.~~

~~19. The dosage form of claim 11, wherein the dosage form, after a single administration to a human subject in need of treatment, thereof produces in the subject a mean a mean area under the curve (0-inf) (AUC_{0-inf}) between about 5334.2 ng·hr/mL to about 7726.7 ng·hr/mL.~~

~~20. The dosage form of claim 11, wherein the dosage form, after a single administration to a human subject in need of treatment, thereof produces in the subject a mean a mean area under the curve (0-inf) (AUC_{0-inf}) between about 5334.2 ng·hr/mL to about 7133.2 ng·hr/mL.~~

~~21. A modified release dosage form comprising:~~

~~80 mg of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof, wherein said dosage form, after a single administration to a human subject in need of treatment thereof produces in the subject a mean maximum plasma concentration (C_{max}) of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof between about 0.113 µg/mL to about 1.29 µg/mL and at least one of: (a) a mean area under the curve (0-inf) (AUC_{0-inf}) between about 5334.2 ng·hr/mL to about 7726.7 ng·hr/mL or (b) a mean time to peak concentration (T_{max}) of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid of between about 1.5 hours to about 3.0 hours.~~

~~22. The dosage form of claim 21, wherein the dosage form exhibits a mean C_{max} of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid of about 1.19 µg/mL and a mean mean time to peak concentration (T_{max}) of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid of about 3.0 hours~~

~~23. The dosage form of claim 21, wherein the dosage form exhibits a mean AUC_{0-inf} of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid in the amount of about 7133.2 ng·hr/mL.~~

~~24. The dosage form of claim 21, wherein the dosage form exhibits a mean C_{max} of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid of about 1.19 µg/mL, a mean T_{max} of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid of about 3.0 hours and a a mean AUC_{0-inf} of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid in the amount of about 7133.2 ng·hr/mL.~~

(e) a delayed release enteric polymer layer encapsulating the immediate release layer comprising a delayed release enteric polymer in an amount ranging from about 17% to about 20% (w/w) of the delayed release bead, said delayed release enteric polymer comprising a mixture of methacrylic acid copolymer type A and methacrylic acid copolymer type B in a ratio ranging from approximately 0.1 to approximately 0.5, and

(f) a plasticizer in an amount ranging from about 1% to about 3% (w/w) of the weight of the delayed-controlled release bead, said plasticizer comprising triethyl citrate.

26. The dosage form of claim 25, wherein the total amount of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof contained in the dosage form is 80 mg.

27. The dosage form of claim of claim 25, wherein said beads are incorporated into an oral dosage form comprising pills, tablets, capsules, and the like.

28. The dosage form of claims 11 or 21 comprising immediate release beads comprising 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof in an amount ranging from approximately 20% to approximately 40% (w/w) of the total composition weight and delayed-controlled release beads comprising 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof having a solubility at pH levels greater than or equal to 6.8 and providing prolonged release of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof over a period of about 4 hours to about 6 hours, in an amount ranging from approximately 60% to approximately 80% (w/w) of the total composition weight,

wherein said immediate release beads comprise

(a) an inert core in an amount ranging from about 50% to about 55% (w/w) of the weight of the immediate release bead, and

(b) an immediate release layer that encapsulates the inert core comprising a mixture of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof and

~~hydroxypropyl methylcellulose in an amount ranging from about 45% to about 50% (w/w) of the weight of the immediate release bead, the ratio of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof to hydroxypropyl methylcellulose ranging from about 1.5 to about 3; and~~

~~wherein said delayed-controlled release beads comprise~~

~~(c) an inert core in an amount ranging from about 34% to about 37% (w/w) of the weight of the delayed-controlled release bead,~~

~~(d) an immediate release layer that encapsulates the inert core comprising a mixture of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof and hydroxypropyl methylcellulose in an amount ranging from about 31% to about 34% (w/w) of the weight of the delayed-controlled release bead, the ratio of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof to hydroxypropyl methylcellulose ranging from about 1.5 to about 2.5,~~

~~(e) a controlled release layer that encapsulates the immediate release layer comprising a controlled release polymer in an amount ranging from about 10% to about 14% (w/w) of the weight of the delayed-controlled release bead, said controlled release polymer comprising a mixture of ethylcellulose aqueous dispersion and hydroxypropyl methylcellulose, the ratio of ethylcellulose aqueous dispersion to hydroxypropyl methylcellulose ranging from about 1.5 to about 3,~~

~~(f) a delayed release pH 6.8 layer that encapsulates the controlled release layer comprising a delayed release pH 6.8 polymer in an amount ranging from about 17.5% to about 20% (w/w) of the weight of the delayed-controlled release bead, said delayed release pH 6.8 polymer comprising a mixture of methacrylic acid copolymer type A and methacrylic acid copolymer type B, the ratio of copolymer type A to copolymer type B ranging from about 0.1 to about 0.5, and~~

(g) a plasticizer in an amount ranging from about 1% to about 3% (w/w) of the weight of the delayed-controlled release bead, said plasticizer comprising triethyl citrate.

29. The dosage form of claim 28, wherein the total amount of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof contained in the composition is 80 mg.

30. The dosage form of claim 28, wherein said beads are incorporated into an oral dosage form comprising pills, tablets, capsules, and the like.

31. The dosage form of claims 11 or 21 comprising immediate release beads comprising in an amount ranging from approximately 10% to approximately 30% (w/w) of the total composition weight and controlled release beads comprising 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof providing prolonged release of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof over a period of about 10 hours to about 12 hours, in an amount ranging from approximately 70% to approximately 90% (w/w) of the total composition weight,

wherein said immediate release beads comprise

(a) an inert core in an amount ranging from about 50% to about 55% (w/w) of the weight of the immediate release bead, and

(b) an immediate release layer that encapsulates the inert core comprising a mixture of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof and hydroxypropyl methylcellulose in an amount ranging from about 45% to about 50% (w/w) of the weight of the immediate release bead, the ratio of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof to hydroxypropyl methylcellulose ranging from about 1.5 to about 3; and

wherein said controlled release beads comprise

(c) an inert core in an amount ranging from about 47% to about 51% (w/w) of the weight of the controlled release bead,

(d) an immediate release layer that encapsulates the inert core comprising a mixture of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof and hydroxypropyl methylcellulose in an amount ranging from about 42% to about 48% (w/w) of the weight of the controlled release bead, the ratio of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof to hydroxypropyl methylcellulose ranging from about 1.5 to about 2.5, and

(e) a controlled release layer that encapsulates the immediate release layer comprising a controlled release polymer, said controlled release polymer comprising a mixture of ethylcellulose and hydroxypropyl methylcellulose in an amount ranging from about 4% to about 8% (w/w) of the weight of the controlled release bead, the ratio of ethylcellulose to hydroxypropyl methylcellulose ranging from about 1 to about 2.

32. The dosage form of claim 31, wherein the total amount of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof contained in the composition is 80 mg.

33. The dosage form of claim 31, wherein said beads are incorporated into an oral dosage form comprising pills, tablets, capsules, and the like.

34. Use of a therapeutically effective amount of the dosage form of claims 11, 21, 25, 28 or 31, in the manufacture of a medicament for treating a patient suffering from gout, hyperuricemia, hypertension, nephrolithiasis, chronic kidney disease, and in need of treatment thereof.